Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ATEA PHARMACEUTICALS, INC.

(AVIR)
  Rapport
Geschatte realtime Cboe BZX  -  17:47:04 27-01-2023
4.565 USD   -0.11%
24/01Atea Pharmaceuticals, Inc. : Morgan Stanley geeft een verkoopadvies
MM
12/01Transcript : Atea Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 03:00 PM
CI
09/01Atea Pharmaceuticals, Inc. Geeft een update over de klinische ontwikkelingsprogramma's voor 2023
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op ATEA PHARMACEUTICALS, INC.
09/01Atea Pharmaceuticals Highlights Strategic Priorities for 2023
09/01Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for ..
04/01Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022Atea Pharmaceuticals Says It Dosed First Patient in Phase 3 Trial of Bemnifosbuvir to T..
2022Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational ..
2022Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrat..
2022Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
2022Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
2022ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
2022Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
2022Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business..
2022Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fev..
2022Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on No..
2022Hepatitis C Virus Infection Pipeline Landscape Analysis of 20+ Companies by DelveInsigh..
2022Sector Update: Health Care Stocks Mixed Premarket Monday
2022Sector Update: Health Care
2022Atea Pharmaceuticals Receives FDA Fast Track for Dengue Treatment
2022Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Tr..
2022Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 ..
2022Atea Gets FDA Fast-Track Designation for AT-752 in Dengue
2022Atea Pharmaceuticals : Bemnifosbuvir Program Update Call Presentation
2022Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-H..
2022Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbu..
2022Atea Pharmaceuticals Announces Upcoming Investor Events
2022Atea Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Provides Business..
2022ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
2022Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
2022Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Busines..
2022Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on A..
2022Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to R..
2022Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped fr..
2022Atea Pharmaceuticals, Inc. : Submission of Matters to a Vote of Security Holders (form 8-K..
2022Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
2022Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ..
2022ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
2022Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 3..
2022Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business..
2022Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on Ma..
20224794 : Characterization of the Toxicity Profile of AT-527 (Bemnifosbuvir), a Novel Guanosi..
20224793 : Lack of Reproductive and Developmental Toxicity for AT-527 (Bemnifosbuvir), an Oral..
2022Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Soci..
2022ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
2022Atea Pharmaceuticals : Reports Fourth Quarter and Full Year 2021 Financial Results and Pro..
2022Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31..
2022Atea Pharmaceuticals : Fourth Quarter 2021 Financial Results Conference Call Presentation
2022Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decemb..
2022Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Pr..
2022Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Confer..
2022Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice Presid..
2022Atea Pharmaceuticals, Inc. Announces Executive Changes
2022Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference
2022Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir's (AT-527) ..
2022Atea Pharmaceuticals, Inc. Announces Publication of Data Supporting Bemnifosbuvir’..
2022Atea Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (..
2022Atea Pharmaceuticals Highlights Strategic Priorities for 2022
2022Atea Pharmaceuticals Highlights Strategic Priorities for 2022
2022Atea Pharmaceuticals, Inc. Provides an Update on the Company’s Clinical Developmen..
2022North American Morning Briefing: Stock Futures -2-
2022Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
2021Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to S..
2021Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) added to N..
2021Atea Pharmaceuticals to Be Added to Nasdaq Biotech Index
2021Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index
2021Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 i..
2021Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 i..
2021Roche: feu vert européen pour le tocilizumab contre le Covid-19
2021Atea Pharmaceuticals, Inc. : Regulation FD Disclosure (form 8-K)
2021Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021Health Care Stocks Manage Modest Gains Wednesday
2021Top Midday Decliners
2021Health Care Stocks Moderately Higher This Afternoon
2021Global markets live: Tesla, Experian, Roche, Activision, Amazon...
2021Bourse Zurich: le SMI poursuit sur la voie des records
2021Atea Pharma Shares Drop 16% After Collaboration With Roche Terminated
2021Wall Street Set to Open Largely Flat, Stabilizing After Boost From Data, Retail Earning..
2021Aktien New York Ausblick: Wenig Bewegung - Unternehmensnachrich..
2021Top Premarket Decliners
2021Atea Pharmaceuticals to Terminate Roche Collaboration for Development of COVID-19 Oral ..
2021Bourse Zurich: le SMI toujours hésitant à l'approche de la mi-journée
2021L'Europe sans direction, l'inflation britannique pèse sur le Footsie
2021Bourse Zurich: ouverture timide, après le record en clôture de mardi
2021Bourse Zurich: ouverture timide attendue après le record en clôture de mar..
2021Roche met un terme à son partenariat avec Atea Pharmaceuticals
2021Roche, Atea Pharmaceuticals Cancel COVID-19 Therapy Development Partnership
2021Atea Pharmaceuticals, Inc. : Termination of a Material Definitive Agreement (form 8-K)
2021Roche walks away from Atea partnership to develop COVID-19 pill
2021Atea Pharmaceuticals to Terminate Roche Collaboration for Joint Development of COVID-19..
2021Atea Pharma says deal to develop COVID-19 pill with Roche terminated
2021Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
2021Atea Pharmaceuticals, Inc. Provides Update on Strategic Collaboration with Roche
2021ATEA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
Volgende evenement op ATEA PHARMACEUTICALS, INC.